Sheila M. D.
- Country
- Spain
- Department
- Rheumatology
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Nipocalimab in Adults with Moderate to Severe Sjögren's Disease
Data & Insights
Has run more than one trial at 82 of 176 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in the treatment and research of Sjögren's Syndrome, with particular emphasis on cases involving moderate to severe systemic manifestations.
- Systemic Disease Management
- Novel Therapeutic Approaches
- Long-term Treatment Strategies
Their clinical focus extends to evaluating innovative treatments for patients experiencing various degrees of disease severity and systemic complications.
Clinical Immunology
The investigator concentrates on understanding and treating systemic manifestations in autoimmune conditions, with specific attention to immune system modulation.
- Immune Response Assessment
- Disease Activity Monitoring
- Treatment Safety Evaluation
Their expertise encompasses the evaluation of immunological interventions for patients with complex autoimmune presentations.
Therapeutic Development
The investigator focuses on assessing novel therapeutic agents for autoimmune disorders, particularly in the context of progressive disease states.
- Treatment Efficacy Analysis
- Safety Profile Assessment
- Long-term Outcomes
Their work involves evaluating the therapeutic potential of emerging treatments for complex autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.